The discovery of non-benzimidazole and brain-penetrant prolylcarboxypeptidase inhibitors.

Abstract Novel prolylcarboxypeptidase (PrCP) inhibitors with nanomolar IC 50 values were prepared by replacing the previously described dichlorobenzimidazole-substituted pyrrolidine amides with a variety of substituted benzylamine amides. In contrast to prior series, the compounds demonstrated minimal inhibition shift in whole serum and minimal recognition by P-glycoprotein (P-gp) efflux transporters. The compounds were also cell permeable and demonstrated in vivo brain exposure. The in vivo effect of compound ( S )- 6e on weight loss in an established diet-induced obesity (eDIO) mouse model was studied.